Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MediWound Ltd. - Ordinary Shares (NQ:MDWD)

17.57 +0.30 (+1.71%)
Streaming Delayed Price Updated: 11:56 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MediWound Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study
MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study
MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
MediWound to Report Second Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Recap: MediWound Q1 Earnings ↗
 
Via Benzinga
News headline image
Earnings Outlook For MediWound ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About MediWound ↗
 
Via Benzinga
News headline image
MediWound Announces Commercial Launch of NexoBrid® in Japan
Kaken Pharmaceutical launches NexoBrid under an exclusive marketing and distribution agreement 
From MediWound Ltd.
Via GlobeNewswire
News headline image
3 Micro-Cap Stocks to Buy for Multibagger Returns ↗
These are the micro-cap stocks to buy and they represent companies with decent fundamentals and visibility for robust growth. 
Via InvestorPlace
News headline image
MediWound Announces Positive Results in Its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Receives Positive Scientific Advice from European Medicine Agency (EMA) on EscharEx Phase III Study Design
Affirms the clear path forward for the Company’s global Phase III study of EscharEx in venous leg ulcers 
From MediWound Ltd.
Via GlobeNewswire
News headline image
Preview: MediWound's Earnings ↗
 
Via Benzinga
Cowen & Co. Maintains Outperform Rating for MediWound: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
FDA Approves MediWound's NexoBrid For Burn Treatment ↗
 
Via Benzinga
News headline image
MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023
From MediWound Ltd.
Via GlobeNewswire
News headline image
Earnings Scheduled For May 30, 2023 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is projected to report earnings for its first quarter. 
Via Benzinga
News headline image
MediWound Reports First Quarter 2023 Financial Results and Provides a Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report First Quarter 2023 Financial Results
Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces an Additional $10 Million Award from BARDA
Funding to support emergency stockpiling replenishment, pediatric indication submission, and expanded access treatment protocol extension 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Reports Fourth Quarter and Full Year 2022 Financial Results and Company Update
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces the Appointment of Hani Luxenburg as Chief Financial Officer
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Report Fourth Quarter and Year-End 2022 Financial Results
Conference Call and Webcast Scheduled for Thursday, March 16 at 8:30 am Eastern Time 
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound to Present Corporate Highlights at Upcoming Investor Conferences
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces Closing of $27.5 Million Registered Direct Offering of Ordinary Shares
From MediWound Ltd.
Via GlobeNewswire
News headline image
MediWound Announces $27.5 Million Registered Direct Offering of Ordinary Shares Priced At-The-Market
From MediWound Ltd.
Via GlobeNewswire
News headline image
Starbucks To Rally 11%? Here Are 10 Other Analyst Forecasts For Wednesday ↗
UBS cut Microsoft Corporation (NASDAQ: MSFT) price target from $300 to $250. UBS analyst Karl Keirstead downgraded the stock from Buy to Neutral. Microsoft shares fell 2% to $234.73 in pre-market... 
Via Benzinga
News headline image
MediWound Announces FDA Approval of NexoBrid® for the Treatment of Severe Thermal Burns in Adults
From MediWound Ltd.
Via GlobeNewswire
News headline image
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors ↗
Biopharma stocks were not immune to the broader market downturn seen for much of 2022. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.